

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: RISE Life Science Corp. (the "Issuer").

Trading Symbol: RLSC

Number of Outstanding Listed Securities: 51,552,622

Date: May 31, 2018

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The Company continues to develop medical and adult-use cannabis-based formulations to create general use health and well-being products for the emerging consumer category made possible by the legal U.S. Farm Bill compliant hemp and the legalization of cannabis. More specifically, with the recent**

introduction of the RISE Report on SEX and Cannabis our longitudinal cannabis and sex study, followed by the launch of our digital publication, RISE Mag (<http://riselifescience.com/rise-mag/>), which just completed featured coverage of the recent Lift event in Toronto, we have already executed against a number of key milestones.

Our targeted product rollout in the California market remains on schedule with an expected launch of our first commercial products into the California market on or about its previously announced launch date of 6/20 2018. Our launch will begin with our suite of CBD sexual health products comprised initially of up to four product SKUs made available in both sublingual tablet and oral spray platforms. In addition to this we expect to introduce follow-on CBD topical products to the California market in early calendar Q3 2018, coinciding with the launch of our full CBD suite of sexual health products in other legal jurisdictions. The Company is also planning a CBD-based beverage line of products in multiple markets within the next 12 months.

Longer term, the Company's goals include establishing the capacity in 2019 to market its full spectrum of CBD products in the United States, Canada and Europe. Beyond 2019, the Company's expansion goals include seeking marketing and manufacturing partnerships in the Asia-Pacific region, while continuing to deepen and expand its range of products.

Of important note, the Company currently intends to only sell THC-based products under license to third parties in the U.S. until federal law pertaining to cannabis is changed. The primary manufacturing and marketing focus will instead be on CBD products derived from the highest quality CBD hemp certified as 'U.S. Farm Bill compliant' enabling the Company to stay completely aligned with U.S. federal law. This class of product may be sold in most U.S. states and in many countries around the world, the Company's intention being that it not be adversely affected in any way by the recent revocation of the 'Cole memo' by the U.S. Department of Justice.

The Company also owns the Scout DS® device which is a clinical tool to assist in the identification of both prediabetes and type 2 diabetes.

2. Provide a general overview and discussion of the activities of management.

**No new activities with respect to management**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**During the month of May, new technologies and administration of cannabis-based products were investigated however, no new commercial products were offered.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**N/A**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**N/A**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**N/A**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from, or the disposition was to, a Related Person of the Issuer, and provide details of the relationship.

**N/A**

8. Describe the acquisition of new customers or loss of customers.

**N/A**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

**N/A**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**N/A**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**N/A**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**N/A**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**N/A**

14. Provide details of any securities issued and options or warrants granted.

<b>Security</b>	<b>Number Issued</b>	<b>Details of Issuance</b>	<b>Use of Proceeds<sup>(1)</sup></b>
Options	670,000	Options were issued with a \$0.40 strike price, 200,000 options vested upon issuance, 50,000 options vest over 12 months and the remaining options vest over 24 months.	N/A

*(1) State aggregate proceeds and intended allocation of proceeds.*

15. Provide details of any loans to or by Related Persons.

**N/A**

16. Provide details of any changes in directors, officers or committee members.

**N/A**

17. Discuss any trends, which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The US Drug Enforcement Agency (DEA) provided clarification that CBD does not fall under the Controlled Substances Act and may be lawfully purchased and sold throughout the United States.**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer, which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 7, 2018.

Robert Lelovic  
Name of Director or Senior  
Officer

"Signed Robert Lelovic"  
Signature  
CFO  
Official Capacity

<b>Issuer Details</b> RISE Life Science Corp.	For Month End May 2018	Date of Report June 7, 2018
Issuer Address 145 King Street West, Suite 210		
City/Province/Postal Code Toronto, Ontario M5H 1J8	Issuer Fax No. ( )	Issuer Telephone No. (416) 302-0779
Contact Name Robert Lelovic	Contact Position CFO	Contact Telephone No. (416) 302-0779
Contact Email Address rlelovic@rogers.com	Web Site Address <a href="http://riselifescience.com/">http://riselifescience.com/</a>	